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1. Abbreviations  
 
ATM  ataxia-telangiectasia mutated 
Apaf-1  apoptosis protease-activating factor-1 
BCNU                        Carmustine 
BSA                           bovine serum albumin 
bp                              base pair 
Cdk-4                        cyclin-dependent kinase-4 
Cip                            CDK inhibitor protein 
CNS                         central nervous system 
DP                            dimerization protein 
Da   Dalton 
DHFR  dihydrofolate reductase 
DNA  Deoxyribonucleic acid  
DTT Dithiothreitol  
EDTA  Ethylenediamine- tetraacetic acid  
EtOH Ethanol  
EGFR  Epidermanl growth factor receptor 
FBS                        Fetal bovine serum  
GBM                      Glioblastoma mulitiforme 
GFP                              Green fluorescent protein 
IgG                      Immunoglobulin G  
INK4                    inhibitor CDK4 
IP                          immunoprecipitation  
IRES         internal ribosome entry site 
kDa                       Kilodalton  
LTR                     long terminal repeat 
LUC                     luciferase 
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M                           Molar  
MRI                     Magnetic resonance imaging 
MDM2                 murine double minute clone 2 
MW                    molecular weight 
min                      minute  
mRNA                messenger-RNA  
NLS                     nuclear localization signal  
 
nM                     nanoMolar  
nt                         nucleotide  
N-terminus          Amino-terminius  
O.D                     Optical density  
ORF                  Open reading frame  
PAGE                   polyacrylamide gel electrophoresis 
 
PBS                 Phosphate buffer saline  
PCR                   Polymerase chain reaction  
PET                   Positron emission tomography 
RNA                 Ribonucleic acid  
RT                     reverse transcription 
SDS          soduim dodeyl sulfate 
siRNA                small-interfering RNA  
ser                      serine amino acid 
TK                   thymidine kinase 
Ub                      ubiquitin  
wt                   wild-type  
μ                    micro  
WHO               world health organization 
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2. Introduction  
 
Of all cancer types, brain tumours probably represent the most 
devastating and difficult-to-treat cancer. Although enormous advances in 
treating other solid cancers, such as lung and breast cancers, highlighted the 
last decade, median survival for glioblastoma muliforme (GBM; the most 
common and aggressive primary brain tumour) stayed nearly the same over 
the last 50 years, averaging ~ 1 year (Hoffman et al., 2006; Thuppal et al., 
2006). Regardless of advances in surgical and imaging techniques, we still 
face multiple problems when treating brain tumours, some because of 
extensive infiltration of tumour cells, their invasion into normal brain 
parenchyma or other sites, and resistance to standard radiation and 
chemotherapy. However, our paramount inability to successfully treat brain 
cancer mostly stems from the lack of understanding of the underlying brain 
tumour biology. Another problem common to diagnosing and thus treating the 
disease results from difficulties in classifying brain tumours often defined by 
histological rather than molecular criteria. For example, histological similar 
primary GBMs arising de novo and secondary GBMs progressing from low- to 
high-grade tumours will be classified and treated the same regardless of the 
vast disparity in molecular characteristic (DeAngelis, 2001; Kleihues & Ohgaki, 
1999) . Although curing brain cancer might be in the distant future, we have 
gained some understanding of genetic and molecular characteristics of human 
brain tumours (Louis et al., 2001). Recent advances in laboratory techniques 
and successful development of brain tumour models faithfully recapitulating 
the human disease shed further light on necessity and sufficiency of genetic 
alterations for brain tumour initiation, progression, and maintenance; help 
identify relevant therapeutic targets; and provide an amenable field for testing 
novel therapeutic agents, translating into a better treatment for brain tumour 
patients. 
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2.1 Brain tumours 
 
 2.1.1 Classification and histology 
 
Normal brain is composed of a variety of cell types, including neurons, 
glia (astrocytes, oligodendrocytes, microglia, and ependymal cells), vascular 
epithelium, and meningeal cells. Primary brain tumours can be classified into 
gliomas, the most common adult brain tumours occurring in the brain 
parenchyma above the tentorium, and medulloblastomas, child or young adult 
cerebellar tumours occurring below the tentorium (Lassman, 2004). 
Intracranial tumous arising from meninges (meningiomas) and tumour 
metastases from systemic cancers (lung, breast, colon) are not considered 
primary brain tumours and will not be discussed.  
 
Depending on morphologic and histologic similarities to the normal 
cells, gliomas can be classified as astrocytic, oligodendrocytic, or mixed, and 
are proposed to arise from the respective cell type (Kleihues & Sobin, 2000; 
Lassman, 2004). The WHO classification divides astrocytic tumours into 
grades 1 to 4, grade 4 GBM being the most aggressive and malignant primary 
glioma. Astrocytic tumours (including GBMs) are composed of glial fibrillary 
acidic protein (GFAP)-expressing cells with fibrillary cytoplasm and angular 
nuclei, whereas GFAP-negative oligodendroglial tumours present uniform 
cells with rounded nuclei. GBM features include microvasular proliferation, 
nuclear atypia, presenceof gliant cells, and pseudopalisading necrosis. 
Histologically indistinguishable but molecularly/ genetically distinct primary 
and secodary GBMs develop as primary de vovo tumours or progress from 
the diffuse grade 2 to anaplastic grade 3 astrocytomas and to secondary 
GBMs. Similar WHO classification subdivides oligodendrogliomas into grade 2 
low-grade and grade 3 anaplastic oligodendrogliomas. Although patients 
withlow-grade gliomas survive for 10 to 15 years, patients with grade 3 
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astrocytomas survive for only 2 to 3 years; the mean survival for patients with 
a GBM is ~ 1 year  (DeAngelis, 2001; Kleihues & Sobin, 2000). 
 
Medulloblastomas, “blue-cell tumours” composed of small cells with 
little cytoplasm, are locally invasive and express synaptophysin and NeuN. 
These cerebellar tumous are classified as desmoplastic, if they contain large-
cytoplasm cell islands in the field of more typical medulloblastomas cells, or as 
large cell, if they contain large pleiomorphic cells. Medulloblastomas show 
good prognosis with a 65% to 85% cure rate and a high possibility of complete 
resection; yet, CSF tumour cell spreading and severe neuroaxis irradiation 
effects still pose a problem (Kleihues & Sobin, 2000; Lassman, 2004). 
 
  
2.1.2 Etiology 
 
The eitology of malignant gliomas is largely unknown. However, there 
are some hereditary tumour syndromes associated with primary brain tumours 
such as neurofibromatoses 1and 2, Li-Fraumeni syndrome and Turcot ‘s 
syndrome (Louis & von Deimling, 1995). Also several occupations, 
environmental carcinogens, and dietary factors have been reported to be 
associated with an elevated glioma risk, but this data is controversial. 
Exposure to therapeutic ionizing radiation has been associated with an 
increased brain tumour risk  (Nygaard et al., 1991; Ohgaki & Kleihues, 2005). 
 
 
2.1.3 Genetic abnormalities 
 
Neoplastic transformation in the central nervous system is a process in 
which the normal control of the cell proliferation and cell-cell interactions are 
lost and a normal cell is transformed into a premalignant cell. This process 
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has been found to be involved in oncogenes, tumour suppressor genes, DNA 
repair genes, and cell death genes. The alterations of these genes are not 
specific in malignant glioma but the combination and accumulation are 
characteristic features (Aguzzi et al., 1995; Maher et al., 2001). 
 
In low grade astrocytomas, overexpression of platelet-derived growth 
factor (PDGF) ligands and receptors is the earliest alteration in the genome 
suggesting that autocrine slimulation, cellular proliferation and migration are 
involved (Guha et al., 1995; Maher et al., 2001). PDGF-receptor 
overexpression is closely correlated with the mutations of tumour suppressor 
gene p53 on chromosome 17p (Hesselager et al., 2003). p53 alterations are 
present in nearly 50% of gr II astrocytomas (Stander et al., 2004). The p53 
gene has an important role in cell cycle arrest, response to DNA damage, 
apoptosis, angiogenesis, and differentiation. Many other growth factors and 
their receptors are overexpressed in astrocytomas including epidermal growth 
factor (EGF), and vascular endothelial growth factor (VEGF) leading to 
microvascular proliferation, as well as an increased tendency to infiltrate and 
migrate (Maher et al., 2001; Plate et al., 1992).Epidermal growth factor 
receptor (EGFR) gene is overexpressed or its receptor is amplified in 50-60% 
of all GBM especially in primary GBMs but in few AAS (Marquez et al., 2004; 
Suzuki et al., 2004). These changes in EGFR facilitate mitogenesis and inhibit 
apoptosis in tumour cells (Nagane et al., 1996). In secondary high grade 
astrocytomas molecular abnormalities have been observed in cell-cycle 
regulatory complex, which includes the p16, cyclin-dependent kinase-4 (cdk-
4), cdk-6, cyclin D1, and retinoblastoma (RB) proteins. Deletions of the 
p16/cdkn2A gene, amplification of cdk-4, and mutations of RB gene lead to an 
uncontrolled progression of the cell cycle from the G1 to the S phase (Maher 
et al., 2001; Nakamura et al., 2001). This pathway is altered in 60% of 
anaplastic astrocytomas and in the majority of GBM (Ichimura et al., 1996). 
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Loss of heterozygosity (LOH) on chromosome 10q is found in over 60% 
of GBM (Ohgaki et al., 2004). The tumour suppressor locus is present in 
chromosome 10 and alterations of PTEN/MMAC-1/TEP-1 gene are found in 
30% of GBMs (Fiano et al., 2004). The alterations in the PTEN gene may 
regulate cell migration, but there may be other tumour suppressor genes in 
the nearby region in chromosome 10 (Karlbom et al., 1993). The most 
characteristic genetics alteration is LOH 1p and 19q in oligodendrogliomas, 
which is evident in 80% of these tumour types. The anaplastic 
oligodendroglioma has usually a similar progression in the associated genetic 
changes as high grade astrocytoma (Reifenberger et al., 1994). Some 
oligoastrocytomas carry tumour suppressor gene p53 mutations related to 
astrocytoma and some have 1p and 19q deletions related to 
oligodendroglioma (Maintz et al., 1997). 
 
 
2.1.4 Current therapeutic approaches 
 
Glioma and medulloblastoma treatments normally include tumours 
resection, histologic examination, radiation therapy, and chemotherapy. The 
most common chemotherapeutic agents used for glioma treatment are DNA 
alkylating cytotoxic drugs such as carmustine [1,3-bis(2-chloroethyl-1-
nitrosourea]; a triple combination of procaranzine, cisplatin, and vincristine; or 
the recently development temozolomide etopside, or lomustine, whereas 
those used for medulloblastoma treatment are cisplatin, cyclophosphamide, or 
vincristine.  
 
  Chemotherapy is a method of treatment where specific chemical 
compounds are used to interfere with tumour cell growth and survival. These 
compounds achieve their effectiveness from their ability to alter the cell cycle 
or kill the cell. Both these rely on the fact that tumour derived cells are actively 
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dividing, whereas normal brain cells mostly are not. Therefore, non-dividing 
cells are usually unaffected by chemotherapy. However, the success of the 
treatment depends on dividing rate of cancer cells and thus, fraction of cells in 
this phase of the cell cycle.  
However, drugs listed above present serious side effects and 
eventually fail as patients develop resistance, whereas radiation and 
chemotherapy adversely affect neurocognitive and physical development (Hu 
& Holland, 2005; Weiss et al., 2003). 
 
 
2.1.5 Animal models and in vivo imaging technologies 
 
In vivo modeling provides essential tumour host interactions and is a 
more accurate means of modeling human cancer. Mouse models can be 
classified as Xenograft tumour models or models of spontaneous tumour 
formation in genetically engineered mice (GEM), and help address issues of 
utmost importance in drug development: toxicity and in vivo antitumour 
effectiveness. Although the Food and Drug Administration does not require 
the latter before proceeding to clinical trials, in vivo modeling of drug efficacy 
is a gold standard required by a majority of pharmaceutical companies 
(Benson et al., 2006; Sellers & Fisher, 1999). 
Pharmacokinetic/pharmacodynamic models based on physiological and 
anatomic representation of bodily organs and drug biochemistry are likely to 
supplement in vivo modeling during future drug development (Andersen, 
1995; Andersen & Krishnan, 1994). 
 
Present imaging tools for living organisms are mostly based on 
nonspecific physiological or metabolic changes rather than on specific 
molecular events (Massoud & Gambhir, 2003). Several imaging technologies 
are available for both humans and animals, including positron emission 
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computed tomography (PET), single-photon emission computed tomography 
(SPECT), magnetic resonance imaging (MRI), computed tomography (CT) 
and ultrasound (US). CT and US are currently used for visualizing anatomical 
structures such as organs or tumours. MRI has several advantages including 
high spacial resolution and the ability to gather a broad range of anatomical, 
molecular and functional information. For molecular imaging, although a 
reporter probe for a specific target can be used in conjunction with MRI, the 
sensitivity is relatively low. PET and SPECT generate low spacial resolution 
images that detect metabolic, molecular and pathological changes with high 
sensitivity, but both require the use of radioisotope tracers. 
 
Bioluminescence imaging (BLI) and fluorescence imaging are not used 
clinically, but they have become established methods in animal experiments to 
monitor grafted tumours (Gross & Piwnica-Worms, 2005; Massoud & 
Gambhir, 2003). Both of these optical techniques use charge-coupled device 
detectors to monitor the visible light emitted from the body of anesthetized 
animals. A reporter gene is engineered to express a protein such as luciferase 
or green fluorescent protein from a specific promoter. The levels of these 
proteins can be measured in vivo and correlated with the activity of the 
promoter in the transgene construct. BLI using luciferase has been widely 
used in cell assay, and is now being applied in living cells and animals. When 
live animals are provided with luciferin (the luciferase substrate) through 
injection, luciferase-expressing cells produce light. Fluorescence imaging is 
visualized using a reporter such as green fluorescence protein and thus 
requires an excitation light to illuminate the animals, but no injection is 
needed. Both techniques are highly sensitive and the background noise is 
minimal for grafted tumours. These reactions are rapid and essentially provide 
real-time imaging.  
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2.2 Cell cycle overview 
 
The process of faithfully replicating the genetic information of a cell and 
its subsequent division into two daughter cells is known as the cell cycle. The 
cell cycle can be envisioned as alternating cycles of interphase, where the cell 
grows in size, synthesizes RNA and proteins, and replicates its DNA, and 
mitosis (M), where the newly replicated cell divides. At times, cells may exit 
the cell cycle after M and remain quiescent in a resting phase (G0). Once the 
cell receives a mitogenic stimulus, cells reenter the cell cycle at gap phase 1 
(G1), a growth phase prior to replication, followed by entry into synthesis (S), 
where the DNA of the cell is replicated, succeeded by gap phase 2 (G2), a 
growth phase preceding cell division in M (Figure 1). Progression through the 
four stages of the cell cycle is ordered and tightly regulated to ensure that only 
one round of DNA replication occurs per cell cycle and that cell division only 
occurs after replication is complete. To combat stressors that cells may 
encounter as they progress through the cell cycle, such as misaligned 
chromosomes or damaged DNA, cells elicit checkpoints that halt cell cycle 
progression and allow the cell to try and amend the problem. However, if the 
damage is too severe or if repair is untimely, cells will either undergo 
apoptosis, which is a programmed cell death, or become senescent, which is 
a state of permanent arrest. Cell cycle arrest and elimination of damaged cells 
by apoptosis are extremely important processes to an organism in preventing 
the transmission of damaged or incompletely replicated DNA to new daughter 
cells and thereby acts as a preventative measure against diseases like 
cancer.  
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 Figure 1: The cell cycle 
The cell cycle is divided into four phases (G1, S, G2, and M) and G0   
resting state. Progression through the cell cycle is promoted by 
cyclin-dependent kinases (CDKs), which are regulated positively by 
cyclins and negatively by CDK inhibitors (CDKIs). The restriction 
point is the point at which cells progress through the cell cycle 
independent of external stimuli (Schwartz & Shah, 2005) .  
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2.2.1 Cell cycle regulation by cyclins and cyclin dependent kinases 
 
 Normal cells need to decide when to divide (ie, enter the cell cycle) 
and when to stay in G0. This is a tightly regulated and carefully balanced 
process. The entry into the cell cycle (G1) is historically governed by the 
restriction point- a transition point beyond which cell progression through the 
cell cycle is independent of external stimuli such as exposure to nutrients or 
mitogen activation. This point of determination is thought to divide the early 
and late G1 phase of the cell cycle. 
 
Progression of a cell through the cell cycle is promoted by a number of 
cyclin dependent kinases (CDKs). CDKs are a family of serine-threonine 
protein kinases that control progression of the cell cycle by phosphorylating 
target proteins at specific times (Morgan, 1995; Pines, 1995). Cdk protein 
levels remain constant during the cell cycle, so their activity is regulated by 
expression of the cyclin family of regulatory proteins (Murray, 2004; Pines, 
1991; Pines, 1995). Timed expression and rapid ubiquitin mediated 
proteolysis limits cyclin expression to specific intervals of the cell cycle, 
limiting the activity of the Cdk to certain phases of the cell cycle (Evans et al., 
1983; Glotzer et al., 1991; Murray, 2004; Murray et al., 1989; Reed, 2003). 
During early G1, the cyclin D family (consisting of cyclin D1, D2, and D3) forms 
a complex with Cdk4 or Cdk6. The cyclin D-Cdk4/6 complex begins the cells 
entry into S phase primarily by phosphorylation of the retinoblastoma (Rb) 
family of proteins (Sherr, 1994). This is followed by cyclin E-Cdk2 activity and 
additional Rb phosphorylation pushing the cell from G1 into S phase (Ohtsubo 
et al., 1995). The complex of cyclin A and Cdk2 is required for cells to 
progress through S phase (Girard et al., 1991; Walker & Maller, 1991). In the 
G2 and M phases of the cell cycle cyclin A forms a complex with Cdk1, and 
this complex is required for transition from G2 to M (Yam et al., 2002). Mitosis 
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is then further regulated by activity of the cyclin B-Cdk1 complex (Arellano & 
Moreno, 1997; King et al., 1994) (Figure 1).  
 
Regulation of these cyclin/cdk complexes is accomplished by a variety 
of mechanisms (Lee & Yang, 2001; Pei & Xiong, 2005; Pines, 1991; Pines, 
1995; Sanchez & Dynlacht, 2005). For example, cyclin/cdk complexes are 
regulated by a class of proteins known as cyclin dependent kinase inhibitors 
(CDKi). Cyclin dependent kinase inhibitors play important roles in coordinating 
proliferation during normal development and differentiation, as well as during 
cellular stress (Coqueret, 2003; Lee & Yang, 2001).There are two broad 
classes of CDKi proteins, the INK4 and CIP families (Pei & Xiong, 2005; 
Pines, 1995; Sherr & Roberts, 1999).The INK4 family, including pI6INK4a target 
Cdk4 and Cdk6 and prevent their association with cyclin D (Carnero & 
Hannon, 1998). Without cyclin D association, Cdk4/6 remain inactive and the 
cell cycle is unable to progress through G1 (Quelle et al., 1995; Serrano et al., 
1993). The Cip/Kip family of cyclin dependent kinase inhibitors, including p21 
and p27, are able to inactivate multiple cyclin-Cdk complexes. They are able 
to block cell cycle progression in G1 and, to a lesser extent; S and M phases 
of the cell cycle and thereby help elicit a checkpoint (Harper et al., 1995; 
Hengst & Reed, 1998; Lee et al., 1995; Polyak et al., 1994).  
 
 
2.2.2 The Retinoblastoma Family of Proteins  
 
The Rb protein is a tumour suppressor, which plays a pivotal role in the 
negative control of the cell cycle and in tumour progression. It has been 
shown that Rb protein (pRb) governs the G1/S transition (Figure 2). In its 
active state, Rb is hypophosphorylated and forms an inhibitory complex with a 
group of transcription factors known as E2F-DP (E2F-1, -2,-3), thus controlling 
the G1/S transition. The activity of Rb is modulated by the sequential 
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phosphorylation by CDK4/6-Cyclin D and CDK2/Cyclin E (Malumbres & 
Barbacid, 2001; Schwartz & Shah, 2005). When Rb is partially phosphorylated 
by CDK4/6-CDKs, Rb remains bound to E2F-DP, but this transcription factor 
is still able to transcribe some genes such as cyclin E. Cyclin E then binds to 
CDK2 and this active complex then completely hyperphosphorlates Rb, thus 
releasing the E2F-DP complex and fully activating the E2F transcription 
factors, resulting in transcriptional activation of numerous S- phase proteins, 
such as thymidylate synthase (TS) and dihydrofolate reductase (DHFR).  
 
The mammalian RB “pocket” protein family consists of three members: 
Rb, p107, and p130. Each of the RB members has a unique expression 
pattern during the cell cycle. For example, Rb is present in quiescent cells and 
then slightly accumulates in cycling cells (Shan et al., 1994). Structurally, 
there are regions of amino acid similarity between all three RB members, but it 
is clear that p107 and p130 are more closely related to each other than either 
protein is related to Rb (Classon & Dyson, 2001).  
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Figure 2: Schematic of G1-S phase regulation of the 
eukaryotic cell cycle.  
Hypophosphorylated Rb complexes with the transcription factor 
E2F. CDK2, CDK4, and CDK6 phosphorylate Rb. E2F is 
released, binds to DNA with DP, resulting in E2F-dependent 
transcription for the G1 to S transition (Schwartz & Shah, 2005). 
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2.2.3 The E2F Family of Transcription Factors  
 
The E2F transcription factors are key regulators of cell cycle 
progression and the E2F field has made rapid advances since its advent in 
1986. Yet, while our understanding of the roles and functions of the E2F family 
has made enormous progress, with each discovery new questions arise. 
Traditionally, the perception of these proteins is that they control the 
transcription of gene products required for S phase. However, data generated 
from microarray and chromatin immunoprecipitation analyses have shown that 
E2F proteins actually regulate a diverse set of genes involved in, not only, cell 
cycle transitions, but also differentiation, apoptosis, DNA repair, and 
checkpoint signaling, as well as some unidentified genes (Ishida et al., 2001; 
Ma et al., 2002; Muller et al., 2001; Polager et al., 2002; Ren et al., 2002).  
 
There are now known to be eight E2F family member genes, E2F1-
E2F8 (Figure. 3). In addition, two E2F3 proteins, termed E2F3a and E2F3b, 
are produced from the E2F3 gene through the use of alternative promoters 
(He et al., 2000; Leone et al., 2000). The highest degree of homology among 
the E2F family members occurs in the DNA binding domain, which is 
consistent with the finding that each binds the E2F consensus sequence. 
Nonetheless, there is accumulating evidence that different E2F family 
members bind and regulate distinct but overlapping sets of target genes. 
 
E2F1 through E2F6 require dimerization with one of three DP proteins 
(DP1, DP2/3 or DP4) to form functional transcription factors that bind DNA 
with high affinity (Bandara et al., 1993; Milton et al., 2006; Ormondroyd et al., 
1995; Rogers et al., 1996; Wu et al., 1995; Zhang & Chellappan, 1995). The 
function of the E2F-DP heterodimer is thought to be determined primarily by 
the E2F subunit. The roles of the different DP subunits, including several 
spliced variants of DP2/3 (Ormondroyd et al., 1995; Rogers et al., 1996), in 
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modulating E2F activity are not completely understood. The transcriptional 
activity of E2F1 through E2F5 is regulated through their association with RB or 
the related pocket proteins, p107 and p130. E2F1, E2F2 and E2F3 primarily 
associate with RB and do so when RB is in the hypophosphorylated state 
(Lees et al., 1993). 
 
E2F4 and E2F5 can associate with each of the three pocket proteins 
and the abundance of these complexes changes with the proliferation state of 
the cells (Gaubatz et al., 2000; Moberg et al., 1996). Pocket protein binding 
blocks the transcriptional activity of E2F-DP heterodimers by masking the 
transcriptional activation domains located in the carboxy terminus of E2F1-5.  
 
E2F family members have been divided into several subclasses based 
on their transcriptional regulatory properties on model gene promoters. E2F1, 
E2F2, and E2F3a are often referred to as “activator” E2Fs because they 
transcriptionally activate E2F target genes such as cyclin E. This subclass of 
E2Fs is expressed in a cell cycleregulated manner with maximum levels 
observed in late G1 and early S phase. Another subclass, which includes 
E2F3b, E2F4, and E2F5, are referred to as the "repressor" E2Fs because 
their main function appears to be to repress the transcription of E2F target 
genes when in association with RB family members (Figure 4).This subclass 
is expressed constitutively but transcriptional repression by these factors 
primarily occurs in quiescent and early G1 phase cells. E2F6, E2F7, and E2F8 
also function as transcriptional repressors of E2F target genes but do so 
independent of RB family members (Cartwright et al., 1998; Christensen et al., 
2005; Di Stefano et al., 2003; Logan et al., 2005; Maiti et al., 2005; Morkel et 
al., 1997) 
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Figure 3: Diagrams of the E2F family of transcription factors. 
The highly conserved winged-helix DNA binding domain (DBD) is 
indicated in blue, and the hydrophobic heptad repeat domain required for 
dimerization is shown in pink. The DBD also appears to contribute to 
dimerization. Other domains required for associations with cyclin A/cdk2 
and Rb family members are also indicated. E2F1-E2F6 all bind DNA as 
heterodimers with DP family proteins, while E2F7 and E2F8 appear to 
associate with DNA independent of DP proteins. Note also that mouse 
homologs of human DP-2 are usually referred to as DP-3, and there are 
several differentially spliced isoforms of DP2/DP3 (not shown). There are 
also two known isoforms of E2F7 which differ in their Ctermini (data not 
shown) (DeGregori & Johnson, 2006). 
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It is now becoming clear that this classification of E2Fs as either 
activators or repressors is overly simplistic and does not accurately reflect the 
dynamics of E2F-dependent transcriptional control. Microarray analysis has 
demonstrated that the overexpression of activator E2Fs, such as E2F1, leads 
to the decreased expression of almost as many genes as are induced (Ma et 
al., 2002; Muller et al., 2001; Polager et al., 2002). In at least some cases, 
transcriptional repression by E2F1 is direct and independent of RB (Croxton et 
al., 2002; Koziczak et al., 2000; Weinmann et al., 2001). On the other hand, 
E2F4 and E2F5 associate with several transcriptional co-activators and can 
transcriptionally stimulate E2F target gene promoters when overexpressed 
(Beijersbergen et al., 1994; Ginsberg et al., 1994; Lang et al., 2001; Morris et 
al., 2000). Moreover, recent findings demonstrate that endogenous E2F4 
regulates the expression of some genes during the G1 phase of the cell cycle 
independent of RB family members (Balciunaite et al., 2005). Chromatin 
immunoprecipitation (ChIP) assays are revealing surprising complexity in the 
promoterspecific and context-dependent recruitment of individual E2Fs and 
E2F-associated co-factors. Some gene promoters conform to the widely 
accepted model of transcriptional repression correlating with the binding of 
E2F4/5-p130/p107 complexes in G0 and early G1 and then being replaced by 
E2F1, E2F2, and/or E2F3a in late G1 and S phase when transcription is 
induced (Takahashi et al., 2000). However, many other E2F target gene 
promoters do not fit this model (Balciunaite et al., 2005; Iwanaga et al., 2004; 
Weinmann et al., 2001; Wells et al., 2003).  In summary, several of the E2Fs 
can either activate or repress transcription through the promoter-specific 
recruitment of a variety of co-factors and this does not necessarily occur in a 
cell cycle-regulated manner. 
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 Figure 4: Schematic representation of the E2F transcription factor 
subgroups, their physiological roles and specific binding partners:  
The E2F family is divided into at least four subgroups defined by their 
regulation by pocket proteins and chromatin modifiers, and by their 
physiological function (i.e. activation or repression). 'DP' presents DP1 or 
DP2, 'chromatin modifiers' refer to chromatin-modifying activities binding 
to the pRB family members, such as HDAC. Recent results have shown 
that also E2F7 recruits repressors to E2F-dependent promoters (Attwooll 
et al., 2004). 
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2.2.4 Functional Roles of RB Regulated E2F Activity 
 
E2F was originally discovered as a cellular binding factor at the 
promoter of the adenovirus E2 gene (Kovesdi et al., 1986; Kovesdi et al., 
1987; Yee et al., 1987). E2F-mediated transcription was stimulated by the 
adenovirus E1A protein and these events correlated with two forms of E2F, a 
"free" E2F and a "complexes" E2F (Bagchi et al., 1990). Soon after, Rb was 
found to be a part of the "complexes" E2F (Bagchi et al., 1991; Bandara & La 
Thangue, 1991; Chellappan et al., 1991; Chittenden et al., 1991) and E1A was 
found to bind (Whyte et al., 1988) and inhibit RB (Bagchi et al., 1991; Bandara 
& La Thangue, 1991; Chellappan et al., 1991). These results led to a model 
where the complexes E2F was constituted by RB binding and repressing E2F 
function, and when RB was inactivated, the free E2F was derepressed and 
able to activate transcription. Although these observations held true for the 
activator class of E2Fs, the model needed to be rethought once it was 
observed that E2F/Rb complexes could actively repress transcription (Hamel 
et al., 1992; Weintraub et al., 1992). 
 
Currently, there are three types of E2F complexes: activator 
complexes, inhibited complexes (actively repress), and repressor complexes 
(Figure 5) (Cobrinik, 2005; Dyson, 1998; Nevins, 1998). The activator 
complexes are E2F/DP heterodimers that actively transactivate promoters. 
The inhibited complexes are formed when Rb is bound to the activator 
complex. When Rb binds, it blocks the E2F transactivation domain and makes 
the complex functionally inert. Finally, active repressor complexes are 
generated when RB family members are recruited to DNA and actively 
assemble a repressor activity. 
 
The RB family members mediate repression of E2F fuction three ways. 
One way they exert this function is by directly binding and blocking the 
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transactivation domain of E2F (Flemington et al., 1993; Helin et al., 1993). 
Additionally, RB is known to bind many proteins involved in chromatin 
remodeling, such as DNA methyltransferases and histone deacetylases, 
which actively repress target gene transactivation (Brehm et al., 1998; Luo et 
al., 1998; Magnaghi-Jaulin et al., 1998; Meloni et al., 1999; Sellers et al., 
1995). It has also been observed that RB can physically inhibit pre-initiation 
complexes from forming at promoters, thereby inhibiting adjacent transcription 
factor function (Ross et al., 1999). 
 
There are four known mechanisms by which RB can be inactivated. RB 
inactivation occurs normally during regulated cell cycle progression, where the 
phosphorylation status of RB and activation of cyclin/cdk complexes is 
coordinated with the phase of the cell cycle, as described previously 
(Blagosklonny & Pardee, 2002). The other three mechanisms for RB 
inactivation result in cell cycle deregulation. One way Rb is inactivated is by 
genetic inactivation, as observed in most cancers (Nevins, 2001; Sellers & 
Kaelin, 1997; Sherr, 1996; Sherr & McCormick, 2002). Additionally, viral 
oncoproteins from DNA tumor viruses target the RB proteins (Helt & Galloway, 
2003). Finally, Rb is degraded by caspases following apoptotic stimuli (Dou & 
An, 1998). 
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 igure 5: Schematics of the three types of E2F complexes. 
(A) Binding of Rb/E2F complexes to E2F regulated promoters 
represses E2Fs transactivation function. (B) By recruiting chromatin 
remodeling enzymes such as HDACs complexes to promoter 
regions, Rb is able to actively repress transcription. (C) Dissociation 
of Rb from E2F allows expression from E2F regulated promoters. 
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2.2.5 Cell cycle deregulation and cancer 
 
Long before the mechanisms of cell cycle deregulation by the small 
DNA tumor viruses were known, these viruses were found to be associated 
with tumor formation. Adenovirus was the first human virus identified to induce 
tumors in an animal model (Trentin et al., 1962). In addition to virus-
associated transformation, cancer often results from cellular mutations that 
result in loss of normal growth control and lead to unrestrained proliferation. 
The high frequency of cell cycle regulators mutated in human cancers 
demonstrates the importance of proper cellular growth control for the 
prevention of cancer (Sherr, 1996). The cell cycle mutations most often 
observed in human cancers include overexpression of cellular cyclins, loss of 
cyclin dependent kinase inhibitors, and loss of Rb either by mutation, deletion, 
or inactivation (McDonald & El-Deiry, 2000). 
 
It is interesting to note that although the overall effect of these 
mutations is to inactivate Rb and deregulate E2F, mutations in E2F have only 
recently been found in some rare gastric and colorectal tumors (Iwamoto et 
al., 2004; Suzuki et al., 1999), suggesting that mutation of E2F might be 
detrimental to emerging tumor cells. 
 
 
 2.2.6 Dual properties of E2F-1: Oncogene and tumor suppressor 
 
Among the E2F family members, E2F-1 is unique in its ability to 
regulate a number of key genes that participate in both cell cycle progression 
and apoptosis, raising a potential link with its role in tumorgenesis.  The 
investigations on cells or animals present us with a wonderful paradox that 
E2F1 behaves as both oncogene and a tumor suppressor gene. On one hand, 
enhancement of E2F1 activity in tissue culture cells can stimulate cell 
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proliferation and be oncogenic. On the other hand, E2F-1 has been 
demonstrated as a tumour suppressor by spontaneous development of 
multiple tumours in mice lacking E2F1 (Yamasaki et al., 1996). The biological 
function of E2F-1 is just beginning to emerge. More recently, new approaches 
have identified a large number of E2F1 targeted genes involved not only in 
DNA replication and cell cycle progression, but also in DNA damage repair, 
check point control, apoptosis (La Thangue, 2003; Stevens & La Thangue, 
2003; Trimarchi & Lees, 2002). Thus, E2F-1 is a multi-functional damage 
responsive protein that is involved in numerous aspects of the DNA damage 
response (Figure 6). 
 
 
 2.2.7 DNA damage 
 
Extracellular and intracellular insults such as reactive oxygen species, 
ionizing radiation,and radiomimetic drugs can induce DSBs (double-strand 
breaks) in DNA. Of the many cellular responses to DSBs, regulation of cell 
division by checkpoints received the most at attention initially. Historically, 
checkpoints refer to mechanisms that arrest the cell division cycle in response 
to intracellular conditions such as damaged or incompletely replicated DNA. 
Signals that activate cell cycle checkpoints were later found to activate 
additional cellular responses such as DNA repair and apoptosis. Thus, 
currently, these responses, along with cell cycle regulation by checkpoints, are 
collectively referred to as DNA damage response pathways. 
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2.2.8 E2F1 signaling 
 
A role for E2F-1 in the DNA damage response pathway was suggested 
from experiments in which treating cells with DNA damaging agents increased 
E2F-1 protein levels (Blattner et al., 1999; Hofferer et al., 1999; O'Connor & 
Lu, 2000). This effect exhibits kinetics that closely resembles the induction of 
p53. In turn, these results hinted that E2F-1 and p53 may be regulated 
through a common pathway (Blattner et al., 1999). 
 
We know now that the induction of E2F-1 reflects the fact that E2F-1 is 
targeted and phosphorylated by ataxia telangiectasia mutated/ataxia 
telangiectasia and Rad3-related (ATM/ATR), and Checkpoint2 (Chk2) protein 
kinases (Lin et al., 2001; Stevens et al., 2003) ( Figure 7), both of which are 
integral components of the DNA damage signalling pathway. At present, it is 
unclear whether ATM/ATR and Chk2 kinases co-operate in regulating E2F-1 
activity in response to DNA damage, although it is the case that there is likely 
to be crosstalk between these phosphorylation events. Whilst we await 
resolution to the question of the relationship between ATM/ATR and Chk2 in 
E2F-1 control, it is possible that multiple phosphorylation events ensure that 
effector proteins are recruited and activated only upon complete activation of 
the DNA damage response pathways. For example, ATM phosphorylation 
may be required to prime E2F-1 for subsequent phosphorylation and 
activation by Chk2 kinase. Alternatively, the level of phosphorylation may 
modulate different properties of E2F-1; perhaps phosphorylation by ATM is 
sufficient to signal cell cycle arrest, whereas induction of apoptosis requires 
phosphorylation by both groups of kinases. The fact that multiple 
phosphorylation events apply mainly to targets with pleiotrophic cellular effects 
such as p53 lends some weight to this idea.  
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 Figure 6: A role for E2F-1 in the control of proliferation, apoptosis and 
DNA repair: (a) Under normal circumstances, E2F-1 regulates the expression 
of genes required for cell cycle progression (b) In response to DNA damage, 
E2F-1 is phosphorylated by ATM/ATR and Chk2 kinases, resulting in E2F-1 
stabilisation. The high levels and/or modification of E2F-1 protein reached in 
response to DNA damage may allow the binding and activation of a different 
spectrum of genes involved in the induction of apoptosis (c) E2F-1 plays 
additional roles, perhaps independently of its transcription factor activity, in 
DNA damage repair and replication control (Stevens & La Thangue, 2004) . 
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Figure 7: Domain organisation of E2F-1. Serine residue 31 
(S31) phosphorylated by ATM/ATR, and serine residue 364 
(S364) phosphorylated by Chk2 kinase in response to DNA 
damage are indicated. E2F-1 has an N-terminal cyclinA/Cdk 
binding site, a nuclear localisation signal (NLS), and a binding site 
for the F-box protein Skp2, which is the cell cycle regulated 
component of the ubiquitin protein ligase SCFSkp2. The pocket-
protein binding and trans-activation domain are located in the C-
terminus. The position of the DNA binding, dimerization and 
marked box domains are also shown. The dimerization domain 
allows E2F-1 to interact with its heterodimeric partner, DP-1 
(Stevens & La Thangue, 2004). 
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Nevertheless, the DNA damage responsive phosphorylation of E2F-1 
has been clearly connected with increased E2F-1 protein stability and the 
induction of apoptosis, in a similar fashion to the control of p53 (Lin et al., 
2001; Stevens et al., 2003). Given the established role of p53 in the DNA 
damage response and checkpoint control, it is highly likely that E2F-1 plays a 
similar role in checkpoint control. 
The DNA damage-induced phosphorylation of p53 has been shown to 
promote the subsequent acetylation of lysine residues within its carboxy-
terminal region, which enhances p53 DNA-binding and transcriptional activity 
(Sakaguchi et al., 1998). The phosphorylation of E2F-1 by ATM/ATR and 
Chk2 kinases may promote a similar outcome, and indeed the acetylation of 
E2F-1 has been connected with phosphorylation by ATM/ATR kinases 
(Pediconi et al., 2003). Degradation via the proteasome requires that proteins 
are first targeted for destruction by the ubiquitination of lysine residues 
(Ciechanover et al., 2000). Thus, it is tempting to speculate that the increase 
in E2F-1 stability observed in response to DNA damage could be the result of 
a phosphorylation-acetylation cascade that prevents the normal turnover of 
E2F-1. 
 Several studies demonstrate that immediately following DNA damage 
induced by IR or genotoxic drugs, DNA damage proteins relocalize to sites of 
the double-stranded DNA breaks, for example, the MRN  complex, 53BP1 
(Nelms et al., 1998; Shiloh, 2003). A consequence of these events is the 
activation of a cell cycle check point pathway through p53/p21CIP that is 
dominant to E2F1-mediated apoptosis (Figure 8). To date, three pathways of 
E2F1 induced apoptosis has been documented, which are (1) a p53-
dependent pathways through stabilization of p53 by E2F1; (2) p53-
independent pathways through direct upregulation of apoptotic related genes 
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by E2F1; (3) blocking of antiapoptotic pathways through downregulation or 
inhibition of antiapoptotic molecules (Bell & Ryan, 2004). 
 
Whilst DNA damage provides a signal for E2F-1 to induce apoptosis, 
the mechanism through which E2F-1 causes apoptosis rather than cell cycle 
progression remains unclear. It has been suggested that different target 
promoters may be occupied by distinct E2F subunits, for example as cells 
progress through the cycle, but to date there is little evidence to support any 
promoter-specificity of E2F complexes (Takahashi et al., 2000). However, a 
recent study investigated E2F-1 gene specificity during the DNA damage 
response, observing that apoptosis-inducing genes like p73 rather than cell 
cycle genes were specifically targeted by E2F-1 upon DNA damage (Pediconi 
et al., 2003). This gene specificity was connected with an increased level of 
E2F-1 acetylation, and required the integrity of the S31 ATM/ATR kinase site 
(Pediconi et al., 2003). It is possible therefore that the DNA damage regulation 
of E2F-1 alters target gene specificity in such a fashion that apoptosis-
inducing genes are favoured, and that the acetylation of E2F-1 plays an 
intimate role in this process.  
Against this background, it remains possible that the level of E2F-1 
protein influences the effects in cells. For example, a threshold E2F-1 level, 
such as the high level reached in response to DNA damage, could determine 
a particular outcome, perhaps by allowing a different spectrum of genes to be 
activated. An equally valid model suggests that DNA damage and subsequent 
phosphorylation promotes the interaction of E2F-1 with accessory proteins, 
resulting in the activation of apoptotic target genes. 
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Figure 8: Model of the relationship between E2F1-mediated 
check point and apoptosis pathway. (a) Dominant pathway 
leading to a cell cycle check point. (b) Apoptosis signaling (Note 
that a subset of factors function in both pathways) (Frame et al., 
2006). 
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When phosphorylated by Chk2, E2F-1 localises to distinct nuclear 
bodies with intense staining (Stevens et al., 2003). In this respect it is known 
that many proteins involved in the recognition and repair of DNA damage, 
including several activated by Chk2, localise to distinct nuclear foci most 
probably at sites of DNA damage (Rouse & Jackson, 2002). However, it is 
unclear if this location is connected with the apoptotic activity of E2F-1 or 
some other property of E2F-1 related to checkpoint control or DNA damage, 
although it is attractive to speculate that E2F-1 may have an additional role in 
the detection of DNA damage and, perhaps, its subsequent repair ( Figure 
6c). In support of this idea, the Mre11–Nbs1–Rad50 checkpoint protein 
complex involved in responses to DNA double stranded breaks (D'Amours & 
Jackson, 2002) associates with E2F-1 through the N-terminal region of Nbs1 
(Maser et al., 2001). Furthermore, the Nbs1/E2F-1 interaction occurs close to 
these sites, suggesting that E2F-1 is required to target the Mre11 complex to 
origins of replication (Maser et al., 2001). Moreover, since Drosophila E2F and 
DP are present in origin recognition complexes (Bosco et al., 2001). It is 
possible that mammalian E2F-1 influences DNA replication upon DNA 
damage.  
A recent study demonstrated that the DNA topoisomerase IIβ binding 
protein 1 (TopBP1) relocalises with E2F-1 to nuclear foci along with BRCA1 in 
response to DNA damage (Liu et al., 2003). The recruitment of E2F-1 to foci 
along with the BRCA1-repair complex and TopBP1 further supports the idea 
that E2F-1 is involved in DNA damage repair and replication control. 
Combined with the earlier discussion, these results imply that E2F-1 is a multi-
functional damage responsive protein that is involved in numerous aspects of 
the DNA damage response. 
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3. Thesis aims 
 
The objective of this dissertation was to non-invasively assess E2F-1 
dependent transcriptional regulation in vitro and in vivo.  
 
It is known that frequently deregulation of the E2F-1 transcription factor 
via alteration of the p16-cyclinD-Rb pathway is a key event in the malignant 
progression of human gliomas. Several recent reports have described that the 
E2F-1 transcription factor serves as a link between Rb/E2F proliferation 
pathway and the p53 signaling pathway. In response to DNA damage, E2F-1 
protein level is increased and induces p53 signaling .This leads to either cell 
cycle arrest followed by DNA repair mechanisms or apoptosis. In this regard, 
the overall goal of investigation was:  
 
• Aim 1: To identify the basal level of E2F-1 expression following      
treatment with BCNU in human U87dEGFR glioma cell line. 
 
• Aim 2:  To generate a self-inactivating retroviral vector which  
carrying Cis-E2F-TA-LITG reporter system.  
 
• Aim 3: To analyze the effect of BCNU in mediating E2F-1/ p53/  
p21 signaling and blocking cell cycle progression. 
 
•  Aim 4: To study the efficacy of the Cis-E2F-TA-LITG reporter   
system by bioluminescent imaging in vitro and in vivo. 
 
Due to the importance of E2F in the regulation of cell cycle progression and 
their deregulation in cancer, these analyses could provide us the feasibility of 
non-invasive monitoring of the kinetics of E2F-1-dependent reporter gene 
expression in vitro and in vivo. 
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4. Results  
 
4.1 E2F-1 expression in U87dEGFR cells is altered in 
response to BCNU treatment  
 
After DNA damage, one consequence of a deregulated pRb/E2F 
pathway is an increase in E2F-1 protein level. To verify this in the 
human U87dEGFR glioma cell line, we measured the E2F-1 protein 
levels in cell extracts prepared from U87dEGFR cells after BCNU 
treatment by immunoprecipitation and Western blot. Proliferating 
U87dEGFR cells were exposed to BCNU (25 μM) and harvested 24h 
and 48h later. E2F-1 protein was immunoprecipitated by using 
monoclonal E2F-1 antibody and protein A/G-agarose. The E2F-1 
protein level was checked by immunoblot analysis. As observed in 
Figure 1A, untreated cells show a basal level of E2F-1 expression 
which increased after exposure to BCNU with a maximum at 24 hours. 
The densitometric quantification of E2F-1 expression as shown in 
Figure 1B demonstrate the quantitative increase relative to the number 
of U87dEGFR cells for three independent experiments. These results 
indicate that BCNU treatment has a significant positive effect on the 
E2F-1 protein level in U87dEGFR cells (p<0.001; Student t test).  
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Figure 1: 
 
(A) A substantial induction of E2F-1 protein level in 
response to BCNU treatment 
 
The E2F-1 protein level was shown in non-treated and BCNU 
treated human U87dGEFR glioma cells at different incubation 
times. The primary anti-E2F-1 antibody recognizes E2F-1 protein 
at approx. 60 kDa (first band). The 55 kDa and 27 kDa heavy and 
light IgG chains, respectively, of the primary antibody were also 
detected. 
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Figure 1: 
 
(B)  A significant positive effect of BCNU on the E2F-1 
protein level in U87dEGFR cells 
 
 The E2F-1 protein level was normalized with respect to 
cell number.Significant differences between BCNU-treated 
and non-treated cells (P<0.001; Student t test) are 
indicated by *. Error bars represent standard deviation. 
The findings depicted in A and B represents the results of 
three independent experiments. 
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4.2 BCNU induces p53 and p21 expression in U87dEGFR 
cells 
 
Given the fact that p53 protein plays an important role in 
protecting cells from the effects of DNA damage, we also evaluated p53 
and p21 protein level in response to BCNU exposure by Western blot 
analysis. As shown in Figure 2, p53 and p21 levels increased in treated 
cells compare to non-treated cells with a maximum at 24h (p53) and 
48h (p21 as downstream target for p53) following exposure to 25μM 
BCNU. Therefore we suspect that in response to treatment E2F-1 
expression results in an increase in endogenous p53 protein levels. 
Activation of p53 may leads in activation of a p21-dependent cell cycle 
checkpoint. 
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p53 
Actin 
p21 
Actin 
Figure 2: 
 Induction of p53 and p21 protein levels in response to BCNU 
treatment.  
Western blot analysis of p53 and p21 levels in non-treated and BCNU 
treated U87dEGFR cells. The level of the actin protein is shown as a 
loading control. Note that, as expected, p53, p21 and actin were 
recognized by antibodies at approximately 50, 20, and 40 kDa, 
respectively. 
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 4.3 Characterization of E2F-1 regulated lucIREStkgfp 
expression in cell culture   
 
To study drug dose- and time-dependent variations of luciferase 
gene expression in cell culture, U87dEGFR cell lines stably expressing 
firefly luciferase (luc) were engineered from different reporter vectors. 
The generation of reporter vectors is described in Materials and 
Methods.  
U87dEGFR cells expressing lucIREStkgfp (LITG) under 
transcriptional control of an E2F-1 responsive promoter (U87dEGFR-
E2F-TALITG = test), minimal TA promoter (U87dEGFR-TA-LITG = non-
regulated negative control), and LTR promoter (U87dEGFR-LITG = 
positive control), respectively, were seeded and treated with and without 
BCNU. Luciferin was added directly to the cell culture medium at 
different time points, and luciferase activity was monitored using the 
IVIS imaging system (Figure 3A). The light intensity was higher in 
U87dEGFR-E2F-TALITG cells as compared to non-regulated 
U87dEGFR-TA-LITG negative control cells. After BCNU treatment the 
bioluminescence signal intensity increased in U87dEGFRE2F-TA-LITG 
cells whereas no obvious change was observed between non-treated 
and BCNU-treated negative and positive control cells (Figure 3A).  
For quantitative analysis of different levels of LITG expression 
(luciferase component) in response to BCNU a microplate reader was 
used. A 3.6-fold difference was observed in U87dEGFR-E2F-TALITG 
cells as compared with non-regulated U87dEGFR-TA-LITG negative 
control cells with respect to the basal bioluminescent signal (Figure 
3B). In U87dEGFR-E2F-TALITG cells the expression of LITG increased 
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4.0-fold in response to BCNU exposure whereas no significant increase 
was observed in negative (U87dEGFR-TA-LITG) and positive 
(U87dEGFR-LITG) control cells (Figure 3B). These findings were 
confirmed by quantification of the relative green fluorescence signal per 
single cell using the MPI-tool imaging software (MPI, 
Cologne,Germany)
4
 showing a significant increase (1.9-fold) of green 
fluorescence in U87dEGFR-E2F-TA-LITG cells in response to BCNU 
treatment (Figure 3C).  
The co-localization of IRES-mediated co-regulated LUC and 
TKGFP protein co-expression in cells carrying the E2F regulated LITG 
construct is depicted in Figure 3D.  
Taken together, these data indicate that the light production from 
E2F stably expressing cells correlate with other indicators of cell cycle 
progression and DNA damage signals. 
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Figure 3:  
 
(A) Bioluminescence imaging of E2F transcriptional activity 
induced in cell culture 
 
E2F-responsive transcriptional activity was imaged by the IVIS 
imaging system. Measurements were made in U87dEGFR-E2F-
TA-LITG glioma cells (first row) in comparison to U87dEGFR-TA-
LITG (middle row) and U87dEGFR-LITG (third row) glioma cells. 
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Figure 3:  
 
(B) Positive effect of BCNU on the Bioluminescence 
output related to E2F transcriptional activity 
 
Relative E2F transcriptional activity is quantitated by 
microplate reader. U87dEGFR-E2F-TA-LITG cells have a 
significantly higher signal in comparison to negative control 
U87dEGFR-TA-LITG cells (t-test; P=0.029).After BCNU 
treatment, luciferase signal increases significantly in E21-
regulated U87dEGFR-E2F-TA-LITG cells (t-test; P<0.001), 
but not in negative and positive control cells. 
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Figure 3:  
 
(C) Intensity of green fluorescence in response to BCNU 
correlates with E2F activity in response to BCNU treatment. 
 
Relative intensity of green fluorescence as recorded in single 
cells by mean of a ROI analysis using MPI-tool imaging 
software4 indicating again a significant induction of luciferase 
signal after BCNU treatment in E2F-1-regulated U87dEGFR-
E2F-TA-LITG cells. 
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Figure 3:  
 
(D) Assessment of the Cis-E2F-TA-LITG reporter system 
by immnuo fluorescence microscopy 
 
Co-localization of LUC and GFP in U87dEGFR-E2F-TA-LITG 
cells as compared with non-regulated negative (U87dEGFR-
TA-LITG) and positive (U87dEGFR-LITG) control cells, 
U87dEGFR cells stably expressing luciferase were subjected 
with anti-LUC and fluorescence microscopy. 
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4.4 BCNU treatment leads an arrest in dose dependency 
manner 
 
Cell cycle arrest is a common response to DNA damaging 
agents. Given the up-regulation of E2F-1 in response to BCNU 
treatment and the role of E2F-1 in cell cycle regulation, we examined 
the possible contribution of alkylation-induced arrest on cell cycle 
progression using flow cytometry. We evaluated the cell cycle 
distributions of U87dEGFR-E2F-TA-LITG cells following exposure to 
different doses of BCNU. As shown in Figure 4, 24h after exposure 
there was a dramatic increase in S-phase populations in treated cells 
compared with non-treated cells. In addition, a substantially increase in 
G1-phase was only observed at the highest does of BCNU. 
Accumulation in S/G2 phase following BCNU exposure suggests that 
significant proportion of cells were unable to complete DNA synthesis 
and continue with cell division. Likewise, Cells gave stronger response 
at the highest does of BCNU. 
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           Figure 4:  
Graphs depict cell cycle distributions of U87dEGFR-E2F-TA-
LITG cells.  
Cell cycle distributions were underwent sustained S/G2-phase 
arrest following treatment with different concentrations of BCNU. 
Of note, a greater proportion of cells accumulated in G1-phase at 
the highest BCNU concentration. 
G0/G1: 47,01% G0/G1: 27,94% 
S: 27,81% S: 34,88% 
G2/M: 16,21% G2/M: 20,44% 
  
G0/G1: 20,48% 
S: 43,98% 
G2/M: 24,12% 
 
G0/G1: 18,45% 
S: 44,82% 
G2/M: 25,07% 
 
G0/G1: 36,75% 
S: 40,47% 
G2/M: 11,48% 
 
-BCNU +BCNU 
15 µM 
25 µM 
35 µM 
45 µM 
DNA content 
Cell 
 
number 
                                                                                                Results 
                                                                                                                                               49
4.5 BCNU treatment induces apoptosis  
 
To further investigation, the effect of BCNU in induction of 
caspase-mediated apoptosis was evaluated by measuring the activation 
of caspases- 3/7 in cells treated with BCNU. The semiconfluent 
monolayer of cells was treated with BCNU for 24h to measure the 
induction of caspase-3/7. Although BCNU increased the activities of 
caspase-3/7 in cells with different concentrations of BCNU, the 
activation of caspase-3/7 was significantly more prominent from 25 µM 
BCNU concentrations. The caspase-3/7 activity in cells treated with the 
45 µM concentration was lower, probably due to the cytotoxic effect of 
BCNU at this concentration (Figure 5). 
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Figure 5:    
The effect of BCNU (15-45 µM) on caspase-3 activity in 
U87dEGFR-E2F-TA-LITG cells 
 
The activities of caspase-3/7 were measured using the 
Caspase-Glo 3/7 kit (Promega Corp., Madison, WI) in 
U87dEGFR-E2F-TA-LITG cells. Cells were cultured in 96-well 
plates until they achieved semiconfluency and then treated 
with the indicated concentrations of BCNU for 24h. The 
Caspase-Glo 3/7 reagent (100 µl) was added directly to the 
wells and plates were incubated for 1h before recording the 
luminescence reading. Each value represents the average of 
at least three different values. 
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4.6 Visualization of E2F-1 transcriptional activity in vivo  
 
In order to access the efficacy of the Cis-E2F-TA-LITG reporter 
system in vivo, each cell line was implanted subcutaneously into four 
sites of nude mice: U87dEGFR-E2F-TALITG (test; n=2), U87dEGFR-
TA-LITG (non-regulated negative control; n=2), U87dEGFR-LITG (non-
regulated positive control; n=2). Experiments were repeated twice 
resulting in n=6 animals per cell line. Seven days later, half of the 
animals were injected with BCNU (25 mg/kg, i.p.) to induce E2F activity 
in response to DNA damage. After intraperitoneal administration of 
luciferin, mice were imaged daily with the Xenogen IVIS system (Figure 
6A). As expected, the non-treated test mice bearing U87dEGFRE2F-
TA-LITG gliomas showed a 2.5-fold higher basal intensity of 
bioluminescence signal as compare to mice bearing non-regulated 
U87dEGFR-TA-LITG negative control gliomas. In BCNU-treated test 
mice, a 1.9-fold induction of bioluminescence intensity was observed 
24h after treatment with BCNU. No significant changes were found 
either in non-treated test mice or in negative and positive controls mice 
(Figure 6B). These results indicate that the activity of endogenous E2F-
1 protein and its regulation by an exogenous stimulus (BCNU) in glioma 
cells can be detected and quantified nonnvasively in vivo.  
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Figure 6:  
(A) Bioluminescence imaging of endogenous E2F-1 in vivo 
 
The colour scale represents luminescent signal intensity, with 
blue indicating the least intense and red the most intense light. 
BLI signal increases after addition of BCNU in mice bearing 
U87dEGFR-E2F-TA-LITG gliomas (first row). Negative control 
mice bearing U87dEGFR-TA-LITG gliomas exhibit background 
signal only (second row). Positive control mice bearing 
U87dEGFR-LITG glioma exhibit high BLI signal independent on 
BCNU treatment. 
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Figure 6:  
(B)  Mean of the total bioluminescent signals emitted from s.c. 
tumors in response to BCNU administration. 
 
 Data are representative of 3 independent experiments with n=6 per 
group. Upper- left graph represents data from mice bearing E2F-1 
responsive U87dEGFR-E2F-TA-LITG gliomas. Upper- right graph 
represents data from mice bearing U87dEGFR-TA-LITG negative 
control gliomas. Lower graph represents data from mice bearing 
U87dEGFR-LITG positive control gliomas. Significant differences 
(Student t test; P =0.01) are depicted by *. 
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5. Discussion  
The data presented in this thesis demonstrate the feasibility to non-
invasively assess E2F-1-dependent transcriptional regulation in vitro and in 
vivo. Indeed, we were able to study various levels of E2F-1 expression at 
base line and after exposure to the DNA damaging agent BCNU with its 
known effects on various cell cycle regulating proteins, such as E2F-1, p53 
and p21. We demonstrate that different levels of endogenous E2F-1 activity 
can be quantified and distinguished non-invasively in vivo by molecular 
imaging technology. These findings have important implications for studies 
aiming towards the non-invasive assessment of altered expression of key cell 
cycle regulators in response to molecular targeted therapies.  
 Our data support the several recent reports describing the induction of 
E2F-1 in various cancer cell lines in response to various forms of DNA 
damage such as γ-irradiation, UV-irradiation, and other chemotherapeutic 
drugs (Blattner et al., 1999; Hofferer et al., 1999; Huang et al., 1997; Lin et al., 
2001; Meng et al., 1999). For example DNA damage caused by BCNU, an 
agent which intercalates into DNA, resulting in DNA strand breaks. We also 
found that the E2F-1 protein level significantly increased 24 hours after 
treatment with BCNU (Figure 1 A, B). Our data presented in Figure 2 show 
that p53 and p21 expression were increased following BCNU treatment. 
These observations that BCNU treatment is leading to an increase expression 
of E2F-1, p53 and p21 suggest the contribution of E2F-1 in changing p53 
protein level in response to BCNU. Recent studies also demonstrate that E2F-
1 and p53 are cooperated in response to DNA damage by different 
mechanisms {Powers, 2004 #27; Hershko, 2005 #29}. This may involve a 
number parallel and perhaps synergistic mechanism. For example, a pathway, 
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links integration of E2F1 signaling and activation of the Atm/Chk2/p53 
pathway, offers a mechanism for the proposed involvement of E2F-1 and p53 
resulting from DNA damage. The authors (Blattner et al., 1999; Hofferer et al., 
1999; Huang et al., 1997; Lin et al., 2001; O'Connor & Lu, 2000) argue that  
following treatment of cells with DNA damaging agents, E2F-1 protein 
accumulates and is phosphorylated at an N-terminal Atm recognition 
sequence that is unique to E2F-1 among the E2F family members . This 
phosphorylation of E2F1 is largely dependent on Atm and is required for 
efficient E2F1 stabilization following DNA damage. Chk2 has also been shown 
to phosphorylate and stabilize E2F1 following DNA damage. Accordingly, 
additional studies are required to fully elucidate the combinational effects of 
different mechanisms and the intricate network by which E2F-1 affects the 
level and the activity of p53 in response to BCNU treatment in U87dEGFR-
E2F-TA-LITG cells. 
 
Since an increasing number of reports indicate a so called “yin and 
yang” activity of E2F1 function, it is now obvious that E2F-1 plays a critical 
role in cell cycle arrest and apoptosis (DeGregori & Johnson, 2006; Johnson & 
Degregori, 2006; Stevens & La Thangue, 2004). Therefore, the aim of our 
work was to establish a model system to assess various levels of E2F-1 
activity in the living model in vivo to serve an improved understanding of the in 
vivo kinetics of the cellular response to growth-altering or deathinducing 
agents. To do so, we created an E2F-1 regulated expression system to allow 
the non-invasive monitoring of E2F-1 regulated reporter gene (LITG) 
expression. While a recent paper has shown the possibility to image p53 
transcriptional activity in tumor xenografts by using the Cis-p53TKGFP 
reporter system (Doubrovin et al., 2001), we generated a lucIREStkgfp (LITG) 
reporter system, where expression of LITG is controlled by an E2F-1 
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responsive element. We constructed and tested two self-inactivating retroviral 
vectors bearing the E2F-TA- (test) and a TA- (non-regulated negative control) 
promoter, respectively, controlling the expression of the LITG reporter 
construct. A third retroviral vector bearing LITG under control of the 3’LTR 
promoter served as positive control (material and methods). These vectors 
were used to establish human U87dEGFR glioma cells stabily expressing 
these expression systems. To evaluate the E2F-1-sensitive reporter system, 
we analysed nontreated and BCNU-treated U87dEGFR cells expressing the 
different constructs at different time points using various independent assays: 
fluorescence microscopy, immuno-cytochemisty, and quantification of 
luciferase activity and TKGFP expression (Figure 3A-D) flow cytometry and 
caspase-3 activity (Figure 4, 5). We demonstrate that the Cis-E2F-TA-LITG 
construct is sufficiently sensitive to monitor upregulation of E2F-1 expression 
following treatment with BCNU in U87dEGFR-E2F-TA-LITG cells in culture 
and with these results being in agreement with western blot analysis where 
E2F-1 protein levels were significantly increased 24 hours after treatment with 
BCNU.  
 
A block in cell cycle progression is commonly observed following DNA 
damage when a cell cycle checkpoint is activated to prevent replication of 
damaged DNA (Caspari & Carr, 2002). G2 arrest has been noted previously in 
various cell types in response to the nitrosourease (Tobey, 1975; Tobey & 
Crissman, 1975), including BCNU (Hoshino et al., 1981) and in response to 
some other alkylating agents (Tobey, 1975). Our data implicates that BCNU 
caused two different types of growth inhibition in U87dEGFR-E2F-TA-LITG 
cells (Figure 4). At the low concentrations, there was an accumulation of cells 
in S/G2 phase and a decrease in the G1 population, suggesting mitotic arrest 
at these lower doses. At a high concentration, rapid accumulation of cells in 
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G1 phase occurred within 24 hours. The difference in the effect of BCNU on 
cells at the different concentrations suggests that there may be two distinct 
cytotoxic mechanisms for BCNU at low and at high dosages. Together these 
observations raise the possibility that E2F-1 activation by DNA damage leads 
to block cell cycle progression in part through its ability of activate p53 
resulting in accumulation of p21 protein. We hypothesized that E2F-1 is 
activating a cell cycle checkpoint prior to the induction of apoptosis. It remains 
to be determined if there are differences in p53 activation by E2F-1 that 
mediate either a growth arrest or apoptosis.  
 Due to the fact that treatment with low concentrations of BCNU 
eventually caused growth inhibition and probably also cell death in treated 
cells, a significant caspase-3 activity was not detected with low concentrations 
of BCNU.  It appears that treatment with low concentrations of BCNU initiated 
a process that gradually but irreversibly brings the cells to death, probably 
through inhibiting cell proliferation. In contrast, apoptosis occurred rapidly in 
cells treated with high concentrations of BCNU (Figure 5).  
We speculate that E2F1 may initiate a signalling cascade to activate a 
cell cycle checkpoint and induce a block in cell cycle progression associated 
with redistribution of DNA damage repair molecules. If proper cell cycle 
regulation is not returned, sustained E2F1 activity would then promote 
apoptosis.  
Clinical dosages of BCNU are often limited by toxicity to other organ 
systems, and the actual drug concentrations delivered to tumor sites in vivo 
may be considerably lower than the levels that induce apoptotic pathway. 
However, there is a growing body of evidence showing that deregulation of 
E2F transcription factors is also causatively involved in carcinogenesis, and 
several members of the E2F family are associated with clinical outcome in 
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various cancer entities. Moreover, our observations clearly argue that, under 
certain circumstances, E2F-1 can also be involved in apoptosis by targeting 
key genes in the p53 pathway. We therefore investigated to assess 
quantitatively treatment efficacy and the expression of E2F-1 that is cis-linked 
to the reporter genes in vivo. We assumed that this may offer a better 
understanding of the expression dependent on cell proliferation and apoptosis   
especially as related to E2F-1 activity. 
Most importantly, we have demonstrated that our reporter system is 
sufficiently sensitive for visualization of E2F-1 activity using bioluminescence 
imaging in vivo (Figure 6A-B). Indeed, the up-regulation of E2F signaling 
pathway and luciferase gene expression can be quantified.  These 
observations can be supported by direct analysis of tissue samples. To our 
knowledge, this is the first study of cis- acting enhancer reporter system that is 
distinguishing the activity of enhancer element with the basal viral promoter 
activity. 
 
To conclude, these combined in culture and in vivo results demonstrate 
that the images of the Cis-E2F-TA-LITG reporter system obtained by BLI 
reflect the kinetic changes of the E2F-1 signalling pathway. 
It should be pointed out that recent studies have used E2F-1 apoptotic 
target genes as new therapeutic drug targets thereby providing insight into the 
basic mechanisms of E2F-1-induced apoptosis and its possible clinical 
implications. For example, most tumors lack functional p53 and, therefore, are 
resistant to conventional therapeutic treatment (Hanahan & Weinberg, 
2000).The E2F-1 target genes, especially those that induce apoptosis 
independently of p53 (i.e. p73) (Pediconi et al., 2003), may give rise to the 
development of new forms of molecular therapeutic intervention (Braithwaite 
et al., 2006; Jamshidi-Parsian et al., 2005; Stanelle & Putzer, 2006). In the 
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past few years, preclinical experiments using mainly E2F-1 as an anti-cancer 
therapy have been initiated. The effect of E2F-1 overexpression on tumor 
growth has been evaluated in several types of human cancer. These studies 
have clearly indicated that induction of apoptosis by overexpression of E2F-1 
via adenoviral-mediated gene transfer results in tumor growth suppression. 
Moreover, E2F-1 was shown to sensitize tumor cells to chemotherapy (Dong 
et al., 1999; Fueyo et al., 1998; Kaelin, 2003; Liu et al., 1999). A study by Fine 
et al. described an E2F-1-responsive adenoviral vector for gliomas that 
promises to target cancer cells more specifically than the standard approach, 
thereby reducing the therapy’s toxicity to normal tissue (Parr et al., 1997). 
Since the brain is the central organ to control body function and mind, 
developing improved methods to selectively kill malignant cells while 
preserving the surrounding neuronal tissue would be of considerable value.  
 
In summary, the Cis-E2F-TA-LITG reporter system allows the non-
invasive monitoring of the kinetics of E2F-1-dependent reporter gene 
expression in vivo. The E2F-1 pathway is complex and impacts cellular 
growth, apoptosis, and response to various stimuli, such as DNA damage. 
Little is known about the E2F-1-dependent regulation in vivo, the most of our 
knowledge coming from studies of cultured cell lines. We propose that these 
types of reporter systems, such as Cis-E2F-TA-LITG, will allow a detailed 
insight into the kinetics of cell cycle regulating protein expression in vivo as 
the basis for the further understanding of cell cycle control and for the 
development of new cell cycle targeted molecular therapies.  
While we have made significant advances toward our understanding of 
E2F1 signaling, a number of questions require further exploration. How does 
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expression of E2F1 result in activation of DNA damage response factors? The 
finding that E2F1 may activates both a cell cycle checkpoint and an apoptotic 
response suggests that there may be a molecular switch between the 
divergent outcomes. How the cell decides which pathway to favor remains 
unclear. In addition, E2F-1 may function in multiple pathways in the cellular 
response to DNA damage. Lastly, the exact mechanisms that control E2F 
specificity remain to be determined. It is conceivable that deregulation of both 
proliferation –promoting and proliferation-inhibiting E2F transcription factors 
and their cross-talk is crucially involved in the tumor biology of brain cancer 
and influences clinical outcomes.  
Further studies are warranted to determine the potential role of E2F 
family members in the postulated clinic effect especially as a putative predictor 
in this tumor entity. 
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6. Abstracts 
6.1 Zusammenfasung  
 
Die Deregulierung des E2F-1 Transkriptionsfaktors durch Umbildung 
des p16-cyclinD-Rb Signalweges gilt als wichtiges Ereignis beim malignen 
Fortschreiten der meisten humanen Gliomas. Paradoxerweise erfüllt E2F-1 
die Funktion eines Tumor Supressors und eines Oncogens 
 
Ziel dieser Arbeit war es, nicht-invasiv E2F-1 abhängige 
transkriptionale Regulation in vitro und in vivo nachweisen zu können. 
Zunächst wurde die E2F-1 Expression in U87 dEGFR Zellen nach Induzierung 
von DNA-Schäden mittels BCNU untersucht, die als Antwort auf DNA-
Schädigungen ansteigt. Es konnte in unserem Model gezeigt werden, das der 
E2F-1 Level in diesen Zellen 24 Stunden nach Behandlung mit BCNU 
signifikant erhöht war. Außerdem kann E2F-1 nach DNA-Schädigungen p53 
induzieren, was entweder eine Unterbrechung des Zellzyklus mit 
anschließender Aktivierung der DNA-Reparaturmechanismen, oder Apoptose 
zur Folge hat. Daher wurde der Effekt von BCNU auf den p53 Signalweg und 
die Unterbrechung des Zellzyklus untersucht. Die Analyse zeigte eine Rolle 
für p53 und E2F-1 in der Aktivierung eines p21 abhängigen Zellzyklus 
Kontrollpunktes im Vorfeld der Aktivierung von Apoptose. Um nachzuweisen, 
ob ektopische E2F-1 Expression nicht-invasiv mittels molekularer Bildgebung 
quantifiziert werden kann, wurde nun ein Cis-E2F-TA-LITG Reporter System 
generiert. Die in den folgenden Untersuchungen gewonnen Resultate zeigten 
die Anwendbarkeit und den Nutzen der nicht-invasiven Untersuchung der 
Kinetik der E2F-1 abhängigen Reporter Gen Expression in vitro und in vivo. 
 
Die in dieser Arbeit gemachten Untersuchungen zeigen die Möglichkeit, 
mit Reportersystemen wie dem hier genutzten detaillierte Einsicht in die 
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Kinetik der Zellzykluskontrolle zu erhalten und neue, auf den Zellzyklus 
ausgerichtete molekulare Therapien zu entwickeln. 
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6.2 Abstract 
 
There is strong evidence supporting the theory that deregulation of the 
E2F-1 transcription factor via alteration of the p16-cyclinD-Rb pathway is a 
key event in the malignant progression of most human gliomas. Paradoxically, 
E2F-1 behaves as both an oncogene and a tumor suppressor gene.  
 
Our aim was to non-invasively assess E2F-1 dependent transcriptional 
regulation in vitro and in vivo. Due to the fact that E2F-1 protein level is 
increased in response to DNA damage, we tested the expression of E2F-1 in 
human U87dEGFR glioma cells after induced DNA damage by BCNU. We 
found that the amount of E2F-1 protein significantly increased 24 hours after 
treatment with BCNU. Moreover, E2F-1 can induce p53 following DNA 
damage leading to either cell cycle arrest followed by DNA repair mechanisms 
or apoptosis. Therefore, we analyzed the effect of BCNU in mediating p53 
signaling and blocking cell cycle progression. The analysis revealed a role of 
E2F1 and p53 in activation of a p21-dependent cell cycle check point prior to 
the induction of apoptosis. To determine if ectopic E2F expression non-
invasively can be quantified and distinguished by molecular imaging 
technology, we generated the Cis-E2F-TA-LITG reporter system. Our 
observations address the feasibility of non-invasive monitoring of the kinetics 
of E2F-1-dependent reporter gene expression in vitro and in vivo.  
 
We propose that these types of reporter systems, will allow a detailed 
insight into the kinetics of cell cycle control and for the development of new 
cell cycle targeted molecular therapies. 
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7. Material and Methods  
 
7.1 Glioblastoma cells and culture conditions  
Human U87dEGFR glioma cells with functional wild-type p53 were 
obtained from Dr. W. Cavenee, Ludwig Ins. San Diego (Van Meir et al., 1994). 
The amphotrophic retroviral packaging cell line PHOENIX (kind gift of Dr. 
Nolan, Stanford University) was used for packaging of the retroviral plasmids 
into retrovirus vector particles. The cell lines were grown as monolayer in 
Dulbecco’s modified Eagle medium (DMEM; Life Technologies, Karlsruhe, 
Germany) supplemented with 10% fetal bovine serum (FBS; Roche 
Diagnostics, Mannheim, Germany) and 100 U/ml penicillin and 100 μg/ml 
streptomycin at 37°C in a 5% CO2/95% air atmosphere. Retrovirally 
transduced human U87dEGFR glioma cells were selected with 500 μg/ml 
G418 (PAA Laboratories GmbH, Cölbe, Germany). U87dEGFR-E2F-TA-LITG, 
U87dEGFR-TA-LITG, and U87dEGFR-LITG were obtained by selection in 
culture media supplemented with 2 μg/ml puromycin (Sigma, Taufkirchen, 
Germany).  
 
7.2 Chemotherapeutic agent  
BCNU (Mr 214.06) was purchased from Bristol-Myers Pharmaceuticals 
(München, Germany). A stock solution was prepared by dissolving 100 mg of 
BCNU in 30 ml of 10% ethanol, and was stored at -70°C to ensure drug 
stability (Tepe et al., 1991). Subsequently, BCNU stock solution was added to 
culture medium or was injected intraperitoneally into experimental animals to 
achieve the desired concentrations for experimental use.  
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7.3 Immunoprecipitation  
To estimate the amount of endogenous E2F-1 protein following 
treatment with BCNU, immunoprecipitation was performed. Total cell extracts 
were prepared 0, 24, and 48 hours after BCNU administration. After washing 
(ice cold PBS), cells were resuspended in lysis buffer (10mM Tris pH 8, 1 mM 
EDTA, 1mM DTT, 0.5% Triton) including s instructions. 48 hoursۥby the 
calcium phosphate method according to manufacturer proteinase inhibitor mix 
(Roche Diagnostics GmbH, Mannheim, Germany) and incubated for 30 min 
on ice. Samples were cleared by centrifugation, and supernatants were 
collected. Equal protein amounts were precleared with protein A/G-agarose 
(Santa cruz) for 1 h at 4°C under gentle rotation. Thereafter, 
immunoprecipitation was performed by adding monoclonal anti-E2F1 antibody 
KH95 (Santa Cruz; Heidelberg, Germany) and protein A/G-agarose at 4°C. 
Beads were washed three times (washing buffer) and bound proteins were 
subjected to Western blot analysis. In parallel, non-treated and BCNU-treated 
cells were harvested for determination of cell number as measured by a cell 
counter (Z1 particle counter Beckman, Coulter Krefeld, Germany).  
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7.4 Western blot analyses  
The expression of E2F-1 in response to BCNU treatment was 
evaluated by Western blotting. Briefly, monolayers were harvested 24h and 
48h after BCNU treatment and resuspended in phosphate buffered saline 
(PBS). Cells were lysed and the amount of protein present in each sample 
was quantified using a Bio-Rad protein assay (Bio-Rad Laboratories, 
Hercules, CA). Equal amounts of denatured (95°C, 5 min) protein were loaded 
onto a 10% sodium dodecyl sulfate-polyacrylamide gel. After separation (1 hr, 
100 V) proteins were blotted to a Hybond-ECL membrane (Amersham 
Pharmacia Biotech, Freiburg, Germany) in standard Tris-glycin transfer buffer 
(100 V, 240 mA, 1.25 h). After blocking nonspecific binding (5% nonfat dry 
milk in 0.1% PBS-Tween20; 1 hr) the membrane was washed (0.1% PBS-
Tween20) and then probed with primary antibodies: anti-E2F KH95 at 1:500 
dilution, and anti-actin C-2 at 1:200 dilution (Santa Cruz, Heidelberg, 
Germany), respectively, in 5% dry milk and 0.1% PBS-Tween20 (1 hr). After 
washing, secondary antibodies were applied (Goat Anti-Mouse IgG [Southern 
Biotechnology Associates, Inc., Amersham Munich, Germany] with 
horseradish peroxidase conjugated 1:10.000 in 5% dry milk in 0.1% PBS 
Tween20; 1 hr). For final protein detection chemiluminescent reaction (Pierce 
Biotechnology, Inc., Schwerte, Germany) was used. PCBAS software was 
used to quantify the intensity of protein expression as assessed by Western 
blot.  
 
 
 
 
Material and Methods 
                                                                                                                                               67
 
 
7.5 Generation of reporter vectors  
The schematic structures of the retroviral vectors (pBABEpuro Moloney 
murine leukaemia virus-based vector backbone; kind gift of Dr. Miguel Sena-
Esteves, Harvard Medical School, Boston, USA) are depicted in Figure 1. 
E2F1-TA firefly luciferase cDNA was amplified from pE2F-TA-Luc (test) and 
TA-Luc (negative control) from pTA-Luc (Clontech, Palo Alto, CA) using the 
forward primers 5’- TCT TAC TCG AGC TAG CCT TGG CG- 3’, 5’-CGG GCT 
CGA GAT CTA GAC TCT AGA GGG-3’ respectively and reverse primer 5’- 
CCG CGG ATC CTC TAG AAT TAC ACG GCG A-3’. XhoI (forward primer), 
and BamHI (reverse primer) sites were incorporated into the primers to 
facilitate cloning of fragments. The PCR products (E2F1-TA-luc and TA-luc) 
were digested with XhoI and BamHI and replaced upstream of the TKGFP 
gene into similarly cut pBABE-Neo-IRESTKGFP to generate pBABEneo-E2F-
TA-LITG and pBABEneo-TA-LITG, respectively. A positive clone was 
confirmed by restriction enzyme digestion and DNA nucleotide sequencing. 
Thereafter, the neomycin resistance gene in these vectors was exchanged to 
the puromycin resistence gene using SfiI/NheI restriction sites to generate 
pBABEpuro-E2F-TA-LITG, and pBABEpuro-TA-LITG retroviral vector 
plasmids. To assess the transcriptional activity of the human E2F promoter 
and TA promoter, the selfinactivating feature of the vector was provided by a 
deletion in the 3' LTR enhancer region (U3). During reverse transcription of 
the retroviral RNA, the inactivated 3' LTR is copied and replaces the 5' LTR, 
resulting in inactivation of the 5' LTR enhancer sequences.  
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Structure of retroviral vectors bearing Cis-E2F-TA-LITG, TA-LITG, and 
LITG. In pBABE-E2F-TA-LITG. Tthe expression of the lucIREStkgfp gene is 
regulated by an artificial promoter containing four copies of the E2F enhancer 
element, located upstream of the minimal TA promoter, the TATA box from 
the herpes simplex virus type 1 thymidine kinase promoter. Constitutive 
expression of the puromycin-resistance gene (puro) is driven by the simian 
virus 40 immediate early promoter, allowing for the selection of stably 
transduced cells. Moreover, this vector has a mutation in the 3'LTR (3’dLTR) 
that renders the silencing of its promoter activity after duplication as 5'LTR 
during integration. pBABE-TA-LITG lacks the E2F responsive element and 
serves as non-regulated negative control. pBABE-LITG bears an intact 3’LTR 
and serves as positive conrol.  
 Non-regulated negative 
5‘LTR 
3‘dLTR 
5‘LTR 
Amp 
SV40 
3‘dLTR 
pBABE- 
TA-LITG 
TA 
SV40 
3‘LT
pBABE- 
LITG 
5‘LT
Amp 
LITG 
Positive 
Test vector 
SV40 
pBABE-E2F- 
TA-LITG 
E2F-TA 
LITG 
puro 
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7.6 Packaging and transduction of tumor cell line  
The packaging of pBABEpuro derived plasmids bearing Cis-E2F-TA-
LITG, TA-LITG and LITG into retrovirus particles was performed as described 
previously
25,26
. In brief, PHOENIX cells were grown as monolayers in 60 mm 
dishes and transfected with vector after transfection, the retrovirus containing 
medium was harvested, filtered (0.45μm), stored in aliquots at -80˚ for later 
use or supplemented with polybrene (8μg/ml) (Sigma, Taufkirchen, Germany) 
and used to infect proliferating human U87dEGFR glioma cells.  
 
7.7 Selection of transduced tumor cell clones  
To generate stable cell lines, 48 hours after infection U87dEGFR-E2F-
TA-LITG, U87dEGFR-TA-LITG, and U87dEGFR-LITG glioma cells were 
washed, trypsinized, replated (1:10) and propagated under selection with 
puromycin (2 μg/ml) for 2 weeks.  
 
7.8 Quantification of luciferase gene expression in cell culture  
Cells were seeded at a concentration of 5x10
4 
cells/well in 24-well 
tissue culture plates. D-luciferin (Synchem, Kassel, Germany) at a 
concentration of 2 mg/ml was added immediately prior to the assay. 
Bioluminescence signal was measured using a plate reader (Berthold Tech., 
Bad Wildbad, Germany) and analyzed by Mikro Win 2000 software.  
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7.9 Immunocytostaining  
Cells (2x10
6
) were seeded on coverslips placed in 24 wells and 
incubated for 24 h in DMEM (10% FBS and 1% P/S). The following day, cells 
were washed with PBS (3x5 min), fixed with paraformaldehyd (4%, 20 min) 
and washed with PBS (3x5 min). Cells were permeabilized with 0.2% Triton X-
100 in PBS (3 min) and washed with PBS (3x5 min). Unspecific binding of 
antibodies was prevented by blocking the cells with 3% BSA for 60 min. 
Thereafter, cells were washed with 0.3% BSA/PBS and incubated for 90 min 
with the first antibody (in 0.3% BSA/PBS). Afterwards, cells were washed and 
incubated for 1 h with the secondary antibody (in 0.3% BSA/PBS) and washed 
again (PBS x 5, bidest x 1). Cover slips were removed from the 24 wells put 
on glass slides and sealed using Citi Fluor (Citifluor Ltd, England).  
 
7.10 Flow cytometry analysis 
Cells were plated into 6 cm plates at 1x 106 cells per plate. Cells were 
treated with different concentrations of BCNU. At 24h, cells were trypsinized, 
combined with any floating cells, pelleted, washed twice with PBS, repelleted. 
All centrifugations were at 700 x g for 5 min at 4 C. Subsequently, cells were 
fixed in ethanol (final concentration, 70%) and stored at -20 C. Cells were 
pelleted and washed once with PBS. Cells were resuspended in  0.5 ml PBS 
with RNAse (10 mg/ ml) and incubated for 30min at 37C. Cells were 
processed for propidium iodide (PI) staining (1mg/ml).   Flow cytometric 
analysis was performed on FACs calibur from BD Biosciences. Cell cycle 
profiles were analyzed using Cell Quest software (BD FACSCalibur system). 
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7.11 Caspase-3/7 Assay 
 
The activities of caspase-3/7 were measured using the Caspase-Glo 
3/7 kit ( Promega Corp., Madison, WI). Brifefly, cells were grown in 96-well 
plates until the semiconfluency stage and then treated with indicated 
concentrations of BCNU for 24h in culture medium. Plates were removed from 
the incubator and kept at room temperature for 30 min and the Caspase-Glo 
3/7 reagent (100 µl) was added. Plates were further incubated on a shaker at 
room temperature for 2h and read using a luminometer. 
 
 
 
7.12 Animal experiments  
All animal procedures were performed in accordance with the German 
laws for animal protection and were approved by the local animal care 
committee and the Bezirksregierung Köln. Three equivalent sets of animals (n 
=18 in total) were studied. Each set of animals (n=6) bearing test (n=2), 
negative control (n=2), and positive control (n=2) tumor cells was divided into 
non-treated (n=3) and BCNU-treated animals (n=3). The animals were under 
anesthesia by i.p. injection of ketanest (80 mg/kg) and rompun (16mg/kg). 
Tumor cells (1x10
6 
cells in 50 μl of DMEM) were injected subcutaneously into 
each site in the shoulders and flanks of nude mice (approximately 30g body 
weight) as follows: U87dEGFR-E2F-TA-LITG (test, n=2); U87dEGFR-TA-LITG 
(negative control, n=2) and U87dEGFR-LITG (positive control) giving rise to 4 
tumors per animal. On days 7 to 9 post tumor implantation, xenografts 
reached a size of ~5 mm in diameter, and BCNU (40 mg/kg body weight) was 
injected (i.p.) in 50 % of animals.  
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7.13 Bioluminescence imaging in culture and in vivo  
For the assessment of cells in culture, D-luciferin (Synchem, Kassel, 
Germany) was added to tissue culture medium to a final concentration of 2 
mg/ml. Five minutes later, photons were counted using the IVIS200 imaging 
system (Xenogen, Alameda, CA) according to the manufacturer’s instructions. 
Data were analyzed using LivingImage software (version 2.50, Xenogen). For 
in vivo studies, mice were injected with 200μl of the D-luciferin (20mg/ml) 
solution intraperitoneally. 10 minutes after D-luciferin injection, each mice was 
placed in the specimen chamber mounted with a CCD camera cooled to –
120°C with a field of view (FOV) set at 12.8 cm above the sample shelf. The 
photon emission transmitted from cell samples and mice were measured with 
standard image acquisition times ranging between 1-300 seconds. The gray 
scale photographic images and bioluminescence pseudocolor images were 
superimposed using the LivingImage V  
2.50 software overlay (Xenogen). A region of interest (ROI) was 
performed to quantify different signal intensities.  
 
7. 14 Statistics  
Descriptive statistics and regression analysis were performed with 
Microsoft Excel 2002 (Microsoft Corp). Student‘s t-test as well as Mann-
Whitney Rank sum test were performed with SigmaStat 3.0 (SPSS Inc.); 
statistical significance was set at the less than 5% level (p< 0.05).  
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